Manish R Patel

发表

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.

Suzanne F. Jones, Melissa L. Johnson, D. Spigel, 2023, The oncologist.

Oral Abstract: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

A. Alencar, I. Flinn, P. Zinzani, 2022, Clinical Lymphoma Myeloma and Leukemia.

The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

M. Teufel, M. Gounder, T. Bauer, 2023, Cancer discovery.

HSR23-111: Real-World EGFR Testing in Patients With Surgically Resected Stage I-III Non–Small Cell Lung Cancer (NSCLC) in US Community Oncology Practices

Anne Shah, D. Nickleach, J. Willey, 2023, The Journal of the National Comprehensive Cancer Network.

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

K. Kelly, G. Weiss, A. Heydebreck, 2016 .

Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.

G. Shapiro, F. Meric-Bernstam, J. Infante, 2017 .

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.

I. Avivi, A. Kalota, M. Preis, 2023, Leukemia research.

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study.

P. Zinzani, J. Pagel, K. Izutsu, 2022, Clinical lymphoma, myeloma & leukemia.

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

A. Ruppert, K. Izutsu, W. Wierda, 2023, Blood.

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

D. Juric, D. Mahalingam, D. Peereboom, 2024, Communications medicine.

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.

H. Arkenau, M. Elgadi, R. Aljumaily, 2024, Cancer immunology, immunotherapy : CII.

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

A. Oza, G. Fabbri, J. Saeh, 2023, Molecular cancer therapeutics.